Hemodynamic Optimization Through Pleth Variability Index for OHCA
- Conditions
- Cardiac Arrest With Successful Resuscitation
- Interventions
- Device: Pleth variability indexDevice: Standard non invasive monitoring
- Registration Number
- NCT03841708
- Lead Sponsor
- Stefano Malinverni, MD
- Brief Summary
Less than half of the patients suffering from sudden cardiac arrest arrive at the hospital alive. Within these survivors less than half will be discharged alive from the hospital without being severely disabled.
The most frequent cause of death during the first 24 hours since admission to the hospital is related to cardiovascular instability and failure. In the early phases of ROSC patients are hemodynamically unstable and management for out of hospital cardiac arrests relies on few non invasive measurements such as non invasive blood pressure, SatO2, EtCO2 and continuous ECG. Recent technological advances allow continuous non invasive evaluation of response to fluid challenge in mechanically ventilated patients through the pleth variability index.
The investigators hypothesize that early goal directed therapy based on non invasive measurement of the pleth variability index on top of conventional non-invasive monitor during the initial care in the Emergency Department can improve the hemodynamic status of the participants, increase lactate clearance and reduce fluid balance at 48 hours post arrest.
Objectives:
* To determine whether an early goal directed management based on the pleth variability index on top of standard non invasive hemodynamic monitoring could improve the hemodynamic status of patients post cardiac arrest especially in terms of increase in lactate clearance and reduced fluid balance. Neurological outcome will be investigated.
- Detailed Description
Less than half of the patients suffering from sudden cardiac arrest arrive at the hospital alive. Of these survivors less than half will be discharged alive from the hospital without being severely disabled.
The most frequent cause of death during the first 24 hours since admission to the hospital is related to cardiovascular instability and failure. In the early phases of ROSC from out of hospital cardiac arrest patients are hemodynamically unstable and management relies on few non invasive measurements such as non invasive blood pressure, SatO2, EtCO2 and continuous ECG.
Even at arrival at the ER patients are monitored by non-invasive parameters during the early phases and invasive hemodynamic monitoring may be delayed until ICU admission. Recent technological advances allow continuous non invasive evaluation of response to fluid challenge in mechanically ventilated patients through the pleth variability index.
The research proposal by the investigator is a randomized prospective interventional, single-center study based at Saint Pierre University Hospital, carried out in the emergency department.
Participant will be OHCA admitted alive to the Emergency department with unstable hemodynamics defined as a mean systolic pressure below 70 mmHg or a blood lactate concentration of at least 36 mg/dL (4 mmol/L).
The criteria for exclusion from the study will be pregnancy, being a prisoner or having limitations of therapeutic effort.
During the study the investigators will evaluate whether an hemodynamic protocol based on pleth variability index on top of routine non invasive monitoring is superior to the routine non invasive monitoring only ( such as non invasive blood pressure, EtCO2, SatO2 and ECG) in terms of lactate clearance and fluid balance.
In both study arms the treating clinician will be encouraged to achieve and maintain the following hemodynamics goals: a mean arterial pressure above 70mmHg, a diuresis above 0.5 ml/kg/h, a capillary refill time below 3 and a clearance of lactate above 10% after 2 hours.
In the control arm the participants will be initially resuscitated with an initial bolus of NaCl 0.9% 10ml/kg whenever the patient is not meeting the set hemodynamic goals. If deemed necessary a second fluid challenge of 100 ml of Albumin 20% will be administered to the patient. Any further fluid challenge will be done with NaCl 0.9% 10ml/kg. At any moment the treating clinician will be allowed to initiate a continuous infusion of noradrenaline or dobutamine to achieve the hemodynamic goals. If deemed necessary clinicians will be allowed to perform a cardiac echography at any moment to assess the hemodynamic needs of the patient. Patients will be continuously reassessed to verify that the hemodynamic goals are achieved.
In the intervention arm patient will be resuscitated according to their PVI. Whenever the PVI will be above 13% the patient will be considered as being fluid responsive and a fluid challenge will be performed whenever the patient is not meeting the set hemodynamic goals. First fluid challenge will be an initial bolus of NaCl 0.9% 10ml/kg. If deemed necessary a second fluid challenge of 100 ml of Albumin 20% will be administered to the patient. Any further fluid challenge will be done with NaCl 0.9% 10ml/kg. If the hemodynamic goals are not achieved and the PVI is below 13% an infusion of noradrenaline will be initiated aiming at a mean arterial pressure of at least 70 mmHg. Infusion of dobutamine to achieve the hemodynamic goals will be started according to clinician decision. If deemed necessary clinicians will be allowed to perform a cardiac echography at any moment to assess the hemodynamic needs of the patient.
Patients will be continuously reassessed to verify that the hemodynamic goals are achieved.
In both arms participants will be sedated according to our hospital protocol for OHCA which includes propofol and remifentanyl titrated to achieve a good synchronization between the patient and the ventilator. If despite sedation a good synchronization between the patient and the ventilator cannot be achieved participants will be initially curarized.
Intervention will end at ICU admission when hemodynamic therapeutic decisions will be based on invasive hemodynamic monitoring.
Trainings will be organized for nurses and postgraduate doctors during the months preceding the study to familiarize the medical-nursing team with the study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 82
- Out of Hospital Cardiac Arrest
- ROSC before Emergency department admission
- Mecanically ventilated with a tidal volume of at least 6 ml/IBW
- Admitted to the emergency department with a lactate > 4mmol/L or a mean arterial pressure below 65 mmHg or a TRC>5 seconds
- Minor
- Prisoners
- Pregnant woman
- Atrial fibrillation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pleth Variability Index Pleth variability index In the experimental group patients will be hemodynamically resuscitated in the early phases after ROSC based on the pleth variability index on top of standard non invasive monitoring Standard non invasive monitoring Standard non invasive monitoring In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG.
- Primary Outcome Measures
Name Time Method Change of lactate From ED admission until 6 hours from admission with 1 predefined time point at 3 hours from ED admission Change of lactate at 3h from admission. Lactate clearance will be measured as {(Admission lactate \[mmol/L\] - Lactate at time point \[mmol/L\]) / (Admission lactate \[mmol/L\])} x 100
- Secondary Outcome Measures
Name Time Method Mortality 24h 24 hours Mortality at 24 hours: measured as the rate of mortality during the first 24 hours from ER admission within the two study groups
Mortality 72h 72 hours Mortality at 72 hour:s measured as the rate of mortality during the first 72hours from ER admission within the two study groups
Change of lactate From ED admission until 24 hours from admission with 3 predefined time points at 6,12 and 24 hours from ED admission Change of lactate at 6h 12h and 24h from admission. Lactate clearance will be measured as {(Admission lactate \[mmol/L\] - Lactate at time point \[mmol/L\]) / (Admission lactate \[mmol/L\])} x 100. Patients dying during the observation period will be imputated a lactate clearance of 0
Fluid balance first 48 hours 48 hours Fluid balance at 48 hours post ROSC. Fluid balance will be measured from treatment chart as follows: \[total fluid intake from ER admission to 48 hours post ER admission (crystalloids, colloids, drugs dilution fluids) - total urine output from ER admission until 48th hours since ER admission\]
Fluid balance first 24 hours 24 hours Fluid balance at 24 hours post ROSC. Fluid balance will be measured from treatment chart as follows: \[total fluid intake from ER admission to 24 hours post ER admission (crystalloids, colloids, drugs dilution fluids) - total urine output from ER admission until 24th hours since ER admission\]
SOFA 24 hours 24 hours SOFA at 24 hours post-ROSC: The Sequential Organ Failure Assessment score (SOFA) regroups six different scores one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. It ranges from 0 to 24. Higher values of the score are associated with worse outcome. It will be calculated based on laboratory and clinical values collected closest to the 24th hour since ER admission within the time window going from 18 hours to 30 hours. Since the investigators expect all patients included in this study to be intubated and sedated, GCS would be of limited value and therefore the final CPC score minus 1 will be used as the neurologic failure component.
CPC at hospital discharge At 16 weeks or at hospital discharge whichever comes first CPC at hospital discharge: Cerebral Performance Category (CPC) ranges from 1 to 5. It will be recovered from hospital records describing the clinical condition at the precise moment of patient discharge. Good clinical outcome will be defined as Cerebral performance category 1 or 2 at hospital discharge.
Normalization of lactate 48 hours Time measured in hours it takes from admission to reach a lactate level \< 2mmol/L
Trial Locations
- Locations (1)
CHU Saint Pierre
🇧🇪Bruxelles, Belgium
CHU Saint Pierre🇧🇪Bruxelles, BelgiumStefano Malinverni, MDContact+3225354051stefano_malinverni@stpierre-bru.be